{"id":9953,"date":"2026-02-11T21:25:44","date_gmt":"2026-02-11T21:25:44","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/9953\/"},"modified":"2026-02-11T21:25:44","modified_gmt":"2026-02-11T21:25:44","slug":"novo-nordisk-a-s-trading-in-novo-nordisk-shares-by-board-members-executives-and-associated-persons-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/9953\/","title":{"rendered":"Novo Nordisk A\/S: Trading in Novo Nordisk shares by board members, executives and associated persons"},"content":{"rendered":"

Bagsv\u00e6rd, Denmark, 11 February 2026 – This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company\u2019s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596\/2014 on market abuse. The company\u2019s board members, executives and their associated persons have reported the transactions to Novo Nordisk.<\/p>\n

1 Details of the person discharging managerial responsibilities\/person closely associated a)Name of the Board member\/Executive\/Associated PersonKarsten Munk Knudsen\u00a02 Reason for the notification\u00a0a)Position\/statusExecutive Vice President, Chief Financial Officer (CFO)\u00a0b)Initial notification\/AmendmentInitial notification\u00a03 Details of the issuer\u00a0a)NameNovo Nordisk A\/S\u00a0b)LEI549300DAQ1CVT6CXN342\u00a04 Details of the transaction(s)\u00a0a)Description of the financial instrument,<\/p>\n

type of instrument,<\/p>\n

Shares<\/p>\n

\u00a0<\/p>\n

Get the latest news
\n

\n delivered to your inbox<\/p>\n

Sign up for The Manila Times newsletters<\/p>\n

By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service<\/a> and Privacy Policy<\/a>.<\/p>\n

\u00a0\u00a0Identification codeNovo Nordisk B DK0062498333\u00a0b)Nature of the transactionSale of shares\u00a0c)Price(s) and volume(s)\u00a0Price(s)Volume(s)\u00a0\u00a0\u00a0DKK 315.6026,246\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0d)Aggregated information \u00a0<\/p>\n

26,246 shares<\/p>\n

DKK 8,283,237.60<\/p>\n

\u00a0e)Date of the transaction2026-02-10\u00a0f)Place of the transactionJANE STREET NETHERLANDS B.V. (JNSI)\u00a0<\/p>\n

1 Details of the person discharging managerial responsibilities\/person closely associated a)Name of the Board member\/Executive\/Associated PersonKarsten Munk Knudsen\u00a02 Reason for the notification\u00a0a)Position\/statusExecutive Vice President, Chief Financial Officer (CFO)\u00a0b)Initial notification\/AmendmentInitial notification\u00a03 Details of the issuer\u00a0a)NameNovo Nordisk A\/S\u00a0b)LEI549300DAQ1CVT6CXN342\u00a04 Details of the transaction(s)\u00a0a)Description of the financial instrument,<\/p>\n

type of instrument,<\/p>\n

Shares<\/p>\n

\u00a0<\/p>\n

\u00a0\u00a0Identification codeNovo Nordisk B DK0062498333\u00a0b)Nature of the transactionSale of shares\u00a0c)Price(s) and volume(s)\u00a0Price(s)Volume(s)\u00a0\u00a0\u00a0DKK 315.70311\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0d)Aggregated information \u00a0<\/p>\n

311 shares<\/p>\n

DKK 98,182.70<\/p>\n

\u00a0e)Date of the transaction2026-02-10\u00a0f)Place of the transactionCBOE EUROPE – DXE PERIODIC (NL) (BEUP)\u00a0<\/p>\n

About Novo Nordisk<\/p>\n

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit\u00a0novonordisk.com,<\/a>\u00a0Facebook<\/a>,\u00a0Instagram<\/a>,\u00a0X<\/a>,\u00a0LinkedIn<\/a>\u00a0and\u00a0YouTube<\/a>.<\/p>\n

Contacts for further information<\/p>\n

Company announcement No 10 \/ 2026<\/p>\n

Attachment<\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"Bagsv\u00e6rd, Denmark, 11 February 2026 – This company announcement discloses the data of the transaction(s) made in Novo…\n","protected":false},"author":2,"featured_media":9954,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[1128,141,6748,6004,1312,6747,216,5349,5691,3845,272,1313,512,6746],"class_list":{"0":"post-9953","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-a-s","9":"tag-and","10":"tag-associated","11":"tag-board","12":"tag-by","13":"tag-executives","14":"tag-in","15":"tag-members","16":"tag-nordisk","17":"tag-novo","18":"tag-novo-nordisk","19":"tag-persons","20":"tag-shares","21":"tag-trading"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/9953","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=9953"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/9953\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/9954"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=9953"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=9953"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=9953"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}